Wedbush Estimates Vor Biopharma’s Q1 Earnings (NYSE:VOR)

Vor Biopharma Inc. (NYSE:VOR) – Analysts at Wedbush issued their Q1 2026 EPS estimates for shares of Vor Biopharma in a report issued on Thursday, May 8th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.21) per share for the quarter. Wedbush has a “Neutral” rating and a $0.40 price objective on the stock. The consensus estimate for Vor Biopharma’s current full-year earnings is ($1.42) per share. Wedbush also issued estimates for Vor Biopharma’s Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.20) EPS.

A number of other analysts have also recently issued reports on the company. JMP Securities reissued a “market perform” rating and issued a $6.00 price objective on shares of Vor Biopharma in a research report on Friday, May 9th. HC Wainwright reissued a “neutral” rating on shares of Vor Biopharma in a report on Friday, May 9th. Oppenheimer restated an “outperform” rating and set a $8.00 price objective on shares of Vor Biopharma in a report on Friday, March 21st. Stifel Nicolaus decreased their target price on Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Finally, Jones Trading cut Vor Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $7.06.

Vor Biopharma Trading Down 7.2%

NYSE VOR opened at $0.16 on Monday. The firm’s fifty day moving average price is $0.67 and its two-hundred day moving average price is $0.96. The firm has a market capitalization of $19.98 million, a P/E ratio of -0.10 and a beta of -0.21. Vor Biopharma has a 1 year low of $0.13 and a 1 year high of $1.87.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds have recently bought and sold shares of the company. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Vor Biopharma during the fourth quarter worth $33,000. Money Concepts Capital Corp lifted its position in shares of Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after buying an additional 26,535 shares during the last quarter. Virtu Financial LLC acquired a new stake in Vor Biopharma in the fourth quarter valued at about $60,000. XTX Topco Ltd bought a new position in Vor Biopharma in the fourth quarter valued at about $80,000. Finally, Trustees of Columbia University in the City of New York acquired a new position in Vor Biopharma during the fourth quarter worth about $102,000. 97.29% of the stock is owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.